NSCLC

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

19th Annual New York Lung Cancers Symposium®

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance

Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings

Annual Hawaii Cancer Conference

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

18th Annual New York Lung Cancers Symposium®

22nd Annual Winter Lung Cancer Conference®

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer

LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC

Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies

BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?

Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

26th Annual International Lung Cancer Congress®

Advances In™: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….